Virica Biotech Inc. (“Virica”), a leading developer of cell enhancers for scaling of viral vectors and cell and gene therapies, announces a significant expansion of bioprocessing services through a strategic partnership with Carleton University in a PRESS RELEASE.
“This multi-year, multi-million-dollar research and infrastructure partnership will help drive innovation and talent development in the Ottawa region for the creation and manufacturing of advanced therapies,” said Rafik Goubran, Ph.D., Vice-President (Research and International) and Chancellor’s Professor, Carleton University.
Slated to open this spring, Virica’s new facility at the university multiplies the company’s capacity to provide high throughput virology services for customers looking to optimize production of their cell and gene therapies. In addition to expanded modern infrastructure, this new location enables the development and recruitment of world-class talent with experiential learning and training opportunities for Carleton students.
- Expanded high throughput virology services.
- State-of-the-art analytical research facilities.
- Collaboration with Carleton University for talent development.